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Echinacea spp. are popularly used as an herbal medicine or food supplement for enhancing the immune system. This study shows that plant
extracts from root [R] and stem plus leaf [S+L] tissues of E. purpurea exhibit opposite (enhancing vs inhibitory) modulatory effects on the
expression of the CD83 marker in human dendritic cells (DCs), which are known as professional antigen-presenting cells. We developed a
function-targeted DNA microarray system to characterize the effects of phytocompounds on human DCs. Down-regulation of mRNA expression
of specific chemokines (e.g., CCL3 and CCL8) and their receptors (e.g., CCR1 and CCR9) was observed in [S+L]-treated DCs. Other
chemokines and regulatory molecules (e.g., CCL4 and CCL2) involved in the c-Jun pathway were found to be up-regulated in [R]-treated DCs.
This study, for the first time, demonstrates that E. purpurea extracts can modulate DC differentiation and expression of specific immune-related
genes in DCs.
© 2006 Elsevier Inc. All rights reserved.Keywords: Dendritic cells; Phytocompounds/extracts; Echinacea purpurea; CD markers; Flow cytometry; Gene expression profile; MicroarrayEchinacea, also known as purple coneflower, has become a
top-selling medicinal herb and food supplement in Europe and
the United States [1]. Three major species, E. purpurea, E.
angustifolia, and E. pallida, have been studied for their possible
pharmacological and immunological effects [2–4]. In previous
studies, E. purpurea was reported to increase chemotoxicity in
neutrophils, bactericidal activity against Staphylococcus [5],
and production of TNFα, interleukin (IL)-10, IL-6, and IL-1β in
macrophages [6]. However, the specificity and mechanisms of
the actions of phytocompounds from Echinacea plants on
defined human immune systems remained to be addressed,
mainly because of lack of systematic studies using advanced
cell and gene-based technology [7].
Dendritic cells (DCs) are professional antigen-presenting
cells that play a key role in mediating activities of various⁎ Corresponding authors. Fax: +886 2 2651 5693.
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doi:10.1016/j.ygeno.2006.08.011immune systems, including primary innate immune responses
and T-cell-mediated immune responses [8]. DCs have been
actively investigated recently for use as effectors or adjuvants in
cancer vaccines or cell-based immunotherapy [9]. Investiga-
tions into the specific effects of phytocompounds or herbal
extracts on DCs would be beneficial for translational medicine
research and may provide scientific support for the immune-
modulatory activities of traditionally used or newly identified
medicinal herbs.
Functional genomic approaches have become a new strategy
for biological studies, generally by use of subgenomic (e.g.,≈1/2
of a human genome size, with ∼10,000 genes) DNA microarray
systems. Such DNA microarray technologies can be used to
monitor unclear gene interactions in a global way [10–12].
Previously, several studies utilized DNA microarrays to analyze
differential gene expression inDCs, to survey the cascade actions
of transcriptional induction [13] and to profile changes in gene
expression during DC maturation [14]. In this study, we
developed an oligonucleotide-based array system to evaluate
the differential gene expression patterns in human immature DCs
802 C.-Y. Wang et al. / Genomics 88 (2006) 801–808(imDCs) in response to the immunomodulatory activities of
phytocompounds from E. purpurea extracts.
Herbal medicine has been empirically used for treating
diseases or improving the immune system for ages. However,
until recently, little or no systematic evidence-based research
into a series of anecdotally claimed effects was performed, and
as a result, clear demonstrations of pharmacological efficacy
were often not available. Because E. purpurea is known for its
potential immunostimulatory activity, we studied here the effect
of various tissue extracts of E. purpurea on specific cell-
biological activities of human monocyte-derived DCs. We
evaluated the bioactivity of Echinacea extracts on various cell
surface markers of human DCs, including CD83, CD32, and
HLA-DR, known to be involved in specific cellular and/or
physiological functions of DCs. Furthermore, we also investi-
gated possible modulatory effects of Echinacea extracts on the
gene transcription level in DCs with the use of a home-designed
small-scale gene chip of 225 immune-function-associated or
reference genes. Various genes in the DNA miniarray included
specific chemokines, chemokine receptors, antigen processing
molecules, cytokines, CD markers involved in DC maturation,
molecules involved in immune cell interaction as well as
signaling pathways and apoptosis of DCs, and a group ofFig. 1. Effects of E. purpurea tissue extracts on expression of cell-surface markers in
following extracts: (A) whole plant, (B) stem plus leaf, (C) root, and (D) flower. D
Statistical analyses between vehicle control (0 dosage) and extract treatment (1–500
*p<0.05, **p<0.005, and ***p<0.001.known housekeeping genes. Our results demonstrated that this
small-scale, function-targeted DNA microarray system can be
employed to evaluate the differential gene expression patterns
of DCs in response to treatment with medicinal plant extracts.
Results
Modulatory effects of Echinacea extracts on CD markers of
DCs
Highly purified primary human monocyte-derived dendritic
cells were routinely obtained for analysis of bioactivity of
Echinacea extracts. The addition of cytokines, including GM-
CSF and IL-4, to monocytes in culture can effectively result in
their differentiation into imDCs as indicated by the expression
of CD32 (a representative CD marker for imDCs) and the low
expression level of CD14 (a specific cell-surface marker of
monocytes) (Fig. 1, as seen from the 0 dose of extract
treatments) [14]. Plant extracts of E. purpurea were tested for
their effects on cultured primary imDCs. Figs. 1A–1D show
that the expression levels of CD14 marker in Echinacea extract-
treated imDCs were found to be similar to those of control cells
(not treated). However, dendritic cells treated for 24 h withhuman immature dendritic cells (imDCs). Human imDCs were treated with the
etails of experimental conditions are described under Materials and methods.
μg/ml) were performed using Student’s t test. Significant inhibition is indicated:
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extracts of E. purpurea displayed reduced levels of HLA-DR
and CD32 expression in a dose-dependent manner compared to
the control (untreated) cell samples (Figs. 1A–1D). [W] and [S
+L] extracts showed the greatest CD32 inhibition. At 500 μg/
ml, the expression of CD32 was decreased approximately 30-
to 40-fold (Figs. 1A and 1B). In contrast, only a ≤2-fold
decrease was found with [R] or [F] extracts (Figs. 1C and 1D).
HLA-DR expression was decreased approximately 2.3-fold
with [W] or [S+L] treatment, with only a 0.63- to 0.75-fold
decrease with [R] or [F] treatment. Since the CD32 marker was
greatly affected by [W] or [S+L] extracts, both tissue extracts
could therefore inhibit DC maturation.
We also evaluated the effects of E. purpurea extracts on the
expression of CD83, a key marker for DCmaturation. As seen in
Fig. 2A, treatment with [S+L] or [W] extracts at 500 μg/ml
greatly decreased the expression of CD83, by 68 and 61%,
respectively, in comparison to vehicle (negative control)-treated
DCs. In contrast, the expression of CD83 on DCs treated with
[R] or [F] extracts at 500 μg/ml increased by 43 and 31%,Fig. 2. (A) Differential effects of specific tissue extracts (i.e., whole plant, stem
plus leaf, root, and flower extracts) from different organs of E. purpurea on
CD83 expression in human DCs. (B) Expression of CD83 marker in human DCs
treated with lipopolysaccharide (as a positive control) or vehicle (0.1% DMSO)
control. Statistical analyses between vehicle control (0 dosage) and extract
treatment (1–500 μg/ml) were performed using Student’s t test. Significant
difference is indicated: *p<0.05, **p<0.005, and ***p<0.001.respectively. As seen in Fig. 2B, CD83 expression was increased
approximately 73% by lipopolysaccharide (LPS) (1 μg/ml), a
known stimulant of DC maturation used as a positive control in
this experiment, in comparison to that of the vehicle (control)-
treated imDCs. These results indicate that [R] or [F] extracts of
E. purpurea can promote DC maturation in primary immature
DC cultures, but [W] or [S+L] extracts can inhibit maturation.
To evaluate whether the effects on the expression of CD
markers in DCs could have resulted from a cytotoxic effect of
the extracts, we used a 3-(4,5-dimethythiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide (MTT) assay to examine the viability
of test DCs. At concentrations between 1 and 100 μg/ml, all
extracts, except for [W], were not cytotoxic (Fig. 3). However,
at the highest dose (500 μg/ml), cytotoxicity was detected with
[W] or [S+L] extracts (∼35% decrease in cell viability) but not
with [R] or [F] extracts. Thus, the attenuating effects on CD
marker expression seen with [W] and [S+L] extracts at high
dosage (500 μg/ml) may result in part from the plant extracts’
cytotoxic effects on DCs.
Differential gene expression in DCs as a response to treatment
with Echinacea extract
We used homemade mini-DNA chips, containing 225 genes
with quartet spot-formatted sets of known human immune-
related genes, to collect genomic information on the possible
mechanism(s) of E. purpurea extract-modulated DC activities.
[R] and [S+L] extracts that exhibited opposite (enhanced vs
suppressed) modulatory effects on CD83 expression in imDCs
were used. Since a high concentration of Echinacea extracts
(e.g., [S+L] extract at 500 μg/ml) could result in partially
cytotoxic effects in DCs, we used doses of 100 μg/ml. Results
from three independent experiments showed that normalized
signals at 4 and 16 h post-treatment with [R] or [S+L] extracts
related well and were reproducible. Along with statistical
analysis of the annotation of specific genes and gene clusters, a
summary of our key findings on the differentially expressed
genes in these DCs is shown in Tables 1 and 2. For up-regulated
and down-regulated genes, we considered only those with at
least a 2-fold change in the level of RNA transcript expression in
three independent experiments. Differences in expression were
calculated by dividing the signal intensity values of genes from
[R]- or [S+L]-treated cells by intensity values of genes from
vehicle (control)-treated cells. Among the 225 genes, only 13
genes were up-regulated 2- to 4-fold in [R]-treated imDCs (for
both 4- and 16-h treatments), whereas no genes were down-
regulated in comparison to vehicle-treated cells (Table 1). In
contrast, only down-regulated gene expression was observed in
[S+L]-treated imDCs. Twenty-eight genes were found to be
suppressed between 2.1- to 5.9-fold in [S+L]-treated imDCs in
comparison to cells treated with vehicle (control) only (Table 2).
Metabolite profiling of phytocompounds from tissue extracts of
E. purpurea
To ensure the consistency of the Echinacea extract test in
this study, metabolite profiling of the total 70% ethanolic
Table 2
Down-regulation of genes in dendritic cells with stem-plus-leaf extracts for (A)
4 h or (B) 16 h
Gene Accession number Fold change a (+)/(–) b
(A) 4-h treatment
STAT 1 NM_007315 0.21
FASLG NM_000639 0.24
B2M NM_004048 0.27
IGSF6 NM_005849 0.35
CD34 NM_001773 0.35
IL1B NM_000576 0.40
CD86 NM_175862 0.40
IL10RA NM_001558 0.37
CCL22 NM_002990 0.40
CD1A XM 001763 0.40
BCL2L1 NM_138578 0.41
CCL8 NM_005623 0.41
CLEC1A NM_016511 0.43
LILRB4 NM_006847 0.43
IGF1R NM_000875 0.46
CLEC4A NM_016184 0.48
CCL3 NM_002983 0.49
IFNA1 NM_024013 0.54
CDH8 NM_001796 0.55
CD68 NM_001251 0.55
ITGB1 NM_002211 0.58
WNT1 NM_005430 0.58
(B) 16-h treatment
WNT1 NM_005430 0.17
ETV5 NM_004454 0.19
CCR1 NM_001295 0.36
CCBP2 NM_001296 0.64
a A <0.5-fold change means more than 2-fold change in down-regulation of
gene.
b (+) treatment with plant extract; (–) vehicle control.
Fig. 3. Cell viability of dendritic cells in primary test with tissue extracts
obtained from different organs of E. purpurea. Relative cell viability (%) was
measured at 24 h post-treatment of test cells with vehicle (0.1 or 0.5% DMSO)
or with the indicated doses of tissue extracts from whole plant, stem plus leaf,
root, and flower, with MTT assays. Each data point represents the mean±SE of
three independent experiments. Significant inhibition is indicated: **p<0.005.
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E. purpurea was analyzed with high-performance liquid
chromatography (HPLC) and liquid chromatography/mass
spectrometry (LC/MS) (Fig. 4). Compounds 1 and 2 were
identified as cichoric acid and rutin, respectively, by comparing
their retention time and MS data to those of their respective
authenticated standards. Quantification of compounds 1 and 2,
used as index compounds in this study, in the chromatogram of
a known concentration of the plant extracts was calculated
from a standard calibration curve of the individual index
compounds. The relative content of cichoric acid and rutin was
11.4 and 15.0%, 3.7 and 11.2%, and 3.4 and 9.4% (in dry
weight) for [F], [S+L], and [R] extracts, respectively. The
metabolite profiles and the relative contents of the indexTable 1
Up-regulation of genes in dendritic cells treated with root extracts for (A) 4 h or
(B) 16 h
Gene Accession number Fold change a (+)/(–) b
(A) 4-h treatment
CCL3 NM_002983 2.03
CCL4 NM_002984 2.60
TBX21 NM_013351 2.11
IGF1R NM_000875 2.11
CCL2 NM_002982 2.93
CD1A NM_001763 2.00
ITGAE NM_002208 2.08
(B) 16-h treatment
JUN NM_002228 2.01
CCL2 NM_002982 2.55
ICAM1 NM_000201 2.65
PSCDBP NM_004288 4.16
IL7R NM_002185 4.25
NFATC2 NM_012340 4.32
a A >2.0-fold change means more than 2-fold change in up-regulation of gene.
b (+) treatment with plant extract; (–) vehicle control.compounds were routinely used for quality control of specific
test tissue extracts.
Discussion
E. purpurea is one of the Echinacea species widely used
currently for nutraceutical or pharmaceutical purposes. Various
tissue extracts of this traditional medicinal plant have been
reported to have immunostimulatory activity on a number of
human immune cells, such as macrophages and peripheral
blood mononuclear cells [4,15]. DCs are known to play a key
role in the interface between the innate and the acquired
immune systems. In response to exogenous stimuli (e.g., LPS)
as well as endogenous signals, DCs undergo a programmed
maturation to become efficient, antigen-presenting cells. We
hence investigated whether specific and important cellular and
molecular activities in human DCs could be affected by
treatment with plant extracts from E. purpurea. Our findings
are the first to demonstrate the effects of E. purpurea extracts on
differentiation and modulation of human DCs at the cellular and
subgenomic levels. Results from flow cytometry studies suggest
that the level of CD83 marker expression, a representative
marker of DC maturation, can be significantly enhanced by
treatment with [F] or [R] extracts but that CD83 levels can be
Fig. 4. High-performance liquid chromatogram and candidate index compounds of the 70% ethanolic extracts from flower, stem plus leaf, and root tissues of E.
purpurea. Index compounds 1 and 2 were determined to be cichoric acid and rutin, respectively.
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[W] extracts. This differential effect of [S+L] and [W] tissues
versus [R] and [F] tissues on DC maturation has not been
previously reported.
The promoting activity of [R] extract of E. purpurea on
DC maturation was similar to the effect of LPS on DCs
(Fig. 2), as verified by the expression of CD83 on flow
cytometry. We further examined the gene expression profile
of [R] extract-treated DCs using a homemade mini-DNA
microarray. In previous studies [16,17], the expression of the
chemokines CCL2 and CCL3 and the nonclassical major
histocompatibility complex (MHC) class I-like molecule
CD1A was up-regulated in LPS-simulated DCs. Here we
found that the expression of these three genes was effectively
up-regulated upon treatment with [R] extract of E. purpurea
(Table 1). These results suggest that certain phytocompounds
in the [R] extract may play a role similar to LPS in promoting
the maturation of DCs. The [S+L]-treated imDCs were further
used in mini-DNA microarray assays to characterize whether
specific gene transcriptional activities could be associated with
the suppressive effect of [S+L] extract on DC maturation.
Results in Table 2 show that the chemokines CCL3 and CCL8
and the nonclassical MHC class I-like molecule CD1A were
down-regulated in [S+L]-treated DCs, concomitant with the
inhibitory effect conferred by this tissue extract on CD83
expression. IGF1R, an insulin-like growth factor 1 receptor,
was also up- and down-regulated with [R] and [S+L]
treatment, respectively. These data indicate that CCL3,
CD1A, and IGF1R may be highly regulated or coordinated
with the activity of DC maturation responsive to E. purpurea
extracts.c-JUN, an important transcription factor, previously reported
to be involved in specific cytokine production and the regulation
of DC maturation [18], was up-regulated at the transcriptional
level in [R]-treated DCs. A number of genes involved in
immune cell activation or functions, such as CCL4, IL7R,
NFATC2, TBX21, PSCDBP, ITGAE, and ICAM1, were up-regu-
lated in DCs by treatment with [R] extract (Table 1). The
expression of the chemokine receptors CCR1 and CCR9 and
that of their corresponding chemokines CCL8 and CCL3 were
highly correlated in [S+L]-treated DCs in that they were all
down-regulated (Table 2). Gene products involved in immune
cell interactions or functions, such as CD34 and ITGB1, were
also down-regulated in [S+L]-treated DCs. These results imply
that the [S+L] extract of E. purpurea may be able to attenuate
the adhesion, chemotaxis, or activation functions of specific
immune cell types such as DCs. Interestingly, transcription
factor STAT1, tumor necrosis factor superfamily 6 (FASLG),
β2-microglobulin (B2M), elongation factor WNT1, and tran-
scription factor ETV5 were all significantly down-regulated
(0.17- to 0.27-fold the expression of the vehicle-treated DCs) in
DCs treated with the [S+L] extract. These groups of
immunomodulatory genes thus provide candidates for future
studies of medicinal phytocompounds on human DCs.
Cichoric acid has been reported [15] to be a major compound
present in E. purpurea extract. Fig. 4 shows the LC/MS results
of analysis of the phytocompound profiles of [F], [S+L], and [R]
extracts of E. purpurea. The presence of cichoric acid as a major
constituent of test samples is consistent with previous findings.
However, DCs treated with cichoric acid alone showed no
significant change in CD83 expression (data not shown). We
therefore conclude that cichoric acid is not the key component
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expression of CD83 in DCs. Augmentation/activation of gene
expression by the [R] extract and inhibition by the [S+L] extract
for DC maturation might be conferred by different metabolite
constituents in these two different plant tissue extracts. In our
study we observed that the [R] extract contained a much higher
content of alkylamides (3.01% in dry weight) than the [S+L]
extract (0.10% in dry weight), suggesting that the observed
modulatory effects of root extracts on dendritic cells might be
partly contributed by alkylamide compounds. Echinacea
alkylamides have been reported to modulate TNFα expression
in human monocytes/macrophages via the cannabinoid receptor
CB2, and a number of important signaling molecules, such as
cAMP, JNK, p38/MAPK kinases, ATF-2/CREB-a, and NF-κB,
are involved [18]. We are now investigating whether Echinacea
alkylamides could also exhibit modulatory effects on dendritic
cell differentiation and associated functions.
Taken together, our results show that E. purpurea plants may
confer stimulatory as well as inhibitory effects on specific
biological activities of an important human immune cell system,
DCs. Further fractionation of such stimulatory or inhibitory
bioactivity of phytocompounds from E. purpurea may lead to
identification of a lead phytocompound(s) or enriched subfrac-
tion as therapeutic or adjuvant therapy for DC-mediated
vaccination or immunization, with an ex vivo cell-based
assembly system [9]. Furthermore, the use of crude extracts
or purified phytocompounds for specific, cell- and/or gene-
based immune-regulatory activity studies, as reported here, can
provide a novel strategy for systematic research into immune
cell responsiveness to phytocompounds. Our data demonstrate
that the focused “minichip” approach may be useful for efficient
cross-talk evaluation of the relative gene expression patterns in
DCs as a response to treatment with specific medicinal plant
extracts and phytocompounds. Experimental results obtained
from such studies, as reported here, could provide baseline,
normalizable, and specific information on the future application
of traditional medicinal herbs or the derived phytocompounds
as immune-modulatory therapeutics.
Materials and methods
Plant materials and plant extract preparations and fractionations
Fresh E. purpurea plants in the flowering stage were obtained from a
reputable organic farm in Puli, Taiwan. Plant specimens were deposited as Ep00l
at the Agricultural Biotechnology Research Center, Academia Sinica (Taiwan,
ROC). Fresh plant samples were separated into four parts/groups: whole plant,
stem plus leaf, root, and flower, and each plant material preparationwas extracted
at room temperature with 70% aqueous ethanol for 30 to 40 days, to follow the
traditional Chinese medicine way. The final 70% ethanol-soluble fraction was
collected by centrifugation at 24,000g for 20 min at 4°C and then evaporated to
dryness by Rotavapor. The yield (in percentage dry weight) of [W], [S+L], [R],
and [F] was obtained at 16.3, 18.4, 16.8, and 20.5%, respectively.
Preparation of human DCs and growth in primary cultures
Human peripheral blood mononuclear cells (PBMCs) were isolated from
blood samples drawn from normal healthy volunteers at the Red Cross Blood
Center in Taipei City, Taiwan. Human monocytes were isolated and enriched by
a three-step protocol. Briefly, PBMCs were isolated by centrifugation with aFicoll–Metrizoate density gradient (d=1.077; Amersham Pharmacia Biotech,
Uppsala, Sweden), and collected cells were resuspended and washed twice with
1× phosphate buffered saline (PBS). PBMCs were further enriched by spinning
in Percoll gradient solution (isosmotic solution: PBS/citrate, 11/9) at 1400 rpm
for 30 min. The mononuclear cell layer was collected and washed twice with 1×
PBS buffer, and the enriched PBMC samples were incubated with anti-CD14
monoclonal antibody bound to microbeads and finally purified by passing
through a magnetic cell separation system (Miltenyi Biotec, Germany) with
column type LR. The purity of the PBMCs reached more than 95% CD14+ as
high-quality DC precursor cells. DCs were then prepared by culturing at 37°C in
5% CO2 for 7 days in AIM-V cell growth medium in the presence of human
GM-CSF (1000 U/ml; Peprotaq) and IL-4 (500 U/ml; Peprotaq). Cytokines were
replenished every 3 days. DCs showed high levels of the MHC class I and the
CD86 markers on flow cytometry analysis [19,20]. Purity of DCs from different
batches of preparations was routinely obtained at a range of 92 to 94%
homogeneity.
Treatment of DCs with E. purpurea tissue extracts
Dried plant extracts from different plant organs/tissues of E. purpurea were
dissolved in 100% pure and endotoxin-free dimethyl sulfoxide (DMSO). The
working concentrations of each extract sample were prepared by serial dilutions
to 1, 10, 100, and 500 μg/ml, the final DMSO concentration reached 0.1% in
each DC culture. Individual E. purpurea extract samples were tested for their ex
vivo effect on immature DCs in 1 ml AIM-V growth medium (Gibco BRL,
Rockville, MD, USA), in the presence of 0.1% DMSO. LPS from Escherichia
coli (serotype 055:B5) was purchased from Sigma (St. Louis, MO, USA) and
used as a positive control in the assays [21]. An aliquot of a 0.1% DMSO
solution in medium only was used as a vehicle (negative) control.
Flow cytometry analysis
Immature DCs were treated with the four E. purpurea plant extracts for 24 h
and then harvested and analyzed by double-color immunofluorescence staining.
Monoclonal antibodies against HLA-DR-FITC (Immunotech, Fullerton, CA,
USA) were used to stain the MHC class I molecules. Antibodies against CD14-
PE, CD32-PE, CD83-FITC (Immunotech, Fullerton, CA, USA), and CD86-
FITC (Pharmingen, San Diego, CA, USA) were used for cell flow cytometry
analysis [22]. After cell samples were incubated with test antibody at 4°C for
30 min, cells were washed twice with PBS and fixed with 1% paraformaldehyde.
Dead cells and possibly contaminating lymphocytes were gated out on the basis
of their size and concentration. Analysis involved use of a Coulter EPICS XL
flow cytometer (Beckman–Coulter, NC, USA).
Cell viability assay
Cell viability was assayed by use of the MTT colorimetric dye reduction
method [23–25]. MTT solution was obtained from Sigma. A 5-mg/ml stock
solution in PBS was sterilized by filtration and stocked at −20°C in a darkened
bottle. The testing extracts or phytocompounds were serially diluted (1, 10, 100,
and 500 μg/ml) with the basal cell culture medium in 96-well microculture
plates (50 μl/well), and 4×105 immature DCs/ml in the basal medium (50 μl)
were added to each microwell. All test samples were performed in triplicate per
individual treatment, and test DCs were cultured for 24 h, at 37°C, in a 5% CO2
incubator. Cells in suspension were removed and washed once with 1× PBS
solution, 10 μl of the MTT solution was added to each well, and cells were
cultured for another 4 h at 37°C. Aliquots of 100 μl of 100% DMSO were added
to each well by gentle mixing on a plate mixer for 10 min at room temperature.
The absorbance at 570 nm (OD570) of each well was measured by use of a
multiwell scanning spectrophotometer. The viable DCs were calculated
according to the following formula: viable cell number (%)=OD570 (extract-
treated DCs)/OD570 (vehicle-treated control cells) ×100.
RNA isolation
Immature DCs were isolated from the PBMC preparations. High-purity
(>90%) human monocytes in suspension (1×107 cells) were aliquoted into each
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for 7 days. Cytokine-containing media were replenished on the third day in
culture. After 7 days in primary culture, virtually all (≥96%) monocytes had
differentiated into immature DCs. At this time, conditioned culture media were
removed and the immature DCs were cocultured with test herbal extracts at
100 μg/ml or as specified for 4 to 16 h. The 70% ethanolic extracts from
Echinacea [R] and [S+L] were used in these experiments. RNA samples were
prepared from monolayer cells lysed directly in a culture dish with the use of
Trizol reagent (1×107 cells per milliliter of Trizol reagent) [26]. Briefly, DCs
were collected by stripping the cells using a rubber policeman, lysed with Trizol
reagent, and then extracted with chloroform. The top aqueous phase was
collected by centrifugation at 4°C, 14,000 rpm for 15 min, and RNA was
precipitated from solution by adding an equal volume of isopropanol. RNA
pellets were washed twice with 75% ethanol/DEPC and dissolved in DEPC-
treated water. The concentration and quality of the RNA samples were analyzed
by the relative absorbance of OD260/OD280 and the banding pattern in agarose
gel electrophoresis [27].
Oligonucleotide probe designs
With our design of a focused, function-targeted DNA microarray in a
minichip arrangement, we selected 225 genes involved in chemotaxis
(chemokine and chemokine receptor), antigen processing (receptor for
phagocytosis, molecules for cell adhesion or associated with DC maturation,
homing molecules or molecules for antigen presentation, and other molecules
associated with immune cell interactions), signaling in DCs (TNF superfamily
molecules, receptor-ligand-associated protein kinases, and phosphatase),
apoptosis, other immune-related functions (cytokines, cytokine receptors,
molecules expressed on T cell or myeloid progenitor cells), and housekeeping.
Oligomers were designed with a size of approximately 50 nucleotides to
represent these genes specifically by the U-GET program developed by U-
Vision Biotech, Inc. (Taipei, Taiwan, ROC).
Reverse transcription and first-strand cDNA labeling with amino
allyl-dUTP (AA-dUTP)
A total RNA sample (20 μg) was mixed with 3 μl of Oligo(dT) primer
(Amersham Pharmacia Biotech, UK) and heated at 70°C for 5 min and then
cooled for 10min at room temperature. The reactionmixture (in a total volume of
20 μl) contained 4 μl of 5× first-strand buffer, 2 μl of 0.1 M DTT, 1 μl of a 20×
nucleotide mixture, 1 μl AA-dUTP, and 1 μl of reverse transcriptase Superscript
II (Amersham; CyScribe Post-Labeling Kit). Reverse-transcription reaction was
performed at 42°C for 1.5 h and terminated by the addition of 2 μl 2.5 M NaOH,
followed by incubation at 37°C for 15 min. As a final step, 10 μl of 2 M Hepes
was added to neutralize the reaction. AMicrocon purification kit (Millipore, YM
30) was then used to clean up the synthesized cDNA product. The cDNA pellet
was then speed-vacuum-dried and resuspended in 15 μl water [28].
Labeling of amino allyl-modified cDNA with CyDye
One aliquot of CyDye (Cy3 or Cy5) was resuspended into 15 μl of fresh
0.1 M sodium bicarbonate (pH 9.0) immediately prior to use in a labeling
reaction. The Cy3 dye was added to a tube containing amino allyl-modified
cDNA as the “control” (untreated) sample and the Cy5 to the test (treated)
sample. Samples were mixed by stirring and incubated at room temperature in
the dark for 1 h, and then 15 μl of 4 M hydroxylamine was added to each
coupling reaction, mixed well, and incubated at room temperature in the dark for
another 15 min. Finally, the CyDye-labeled cDNAs were purified with the use of
a DNA purification kit from Qiagen (Cologne, Germany). The allyl-modified
cDNA pellet was then speed-vacuum-dried and resuspended in 5 μl water.
Hybridization and signal detection of oligo-DNA microarrays
The oligo-DNA probe was prepared in a fresh hybridization solution
consisting of 30% formamide, 5× SSC, 0.1% SDS, and 0.1 mg/ml of a nucleic
acid blocker (e.g., human Cot 1 DNA) and then mixed with RNA sample. The
probe and RNA sample solutions were incubated at 95°C for 5 min, centrifugedfor 2 min to collect condensation, and cooled to room temperature for 20 min.
The sample solution was then loaded onto the surface of the printed side of the
array slides and the coverslip was carefully placed on top of the arrays to avoid
creating bubbles. DNA arrays in a hybridization chamber (Corning, Cat. No.
2551) were then placed in a 42°C water bath for 16 h. After incubation, the
arrays were placed in 2× SSC, 0.1% SDS solution at 42°C, washed for 5 min,
and then changed to another wash buffer containing 0.1× SSC and 0.1% SDS at
room temperature for 5 min; the wash was repeated once. In the final step, the
arrays were placed in 0.1× SSC wash buffer at room temperature for 1 min and
the wash was repeated four times. Arrays were dried by centrifugation (800 rpm,
10 min) and analyzed for signals emitted from each spot with digital imaging
software (Genepix 4.0).
HPLC analysis of E. purpurea extracts
The 70% ethanolic extracts of [F], [R], and [S+L] of E. purpurea were
chromatographed over a RP-18 column (Phenomenex Luna 3μ C18,
150×2.0 mm) and detected by UV detection at 330 nm before MS detection.
A 5-μl sample (10 mg/ml) was injected and separated at a flow rate of 0.2 ml/min
with solvent gradient eluted with 0.05% TFA/water (solvent A) and 0.05% TFA/
MeOH (solvent B): 0 to 5% from 0 to 5min, 5 to 20% from 5 to 30min, 20 to 45%
from 30 to 40 min, 45 to 50% from 40 to 50 min. Ionization was performed in the
positive ion mode for all analyses. The mass spectra of the specific compounds 1
(cichoric acid) and 2 (rutin) in the three tissue fractions were characterized with
their pseudo-molecular mass atm/z 497 ([M+Na]+; TR= 36.98 min, compound 1)
and m/z 611 ([M+H]+; TR=40.33 min, compound 2) by use of the
ThermoFinnigan LCQ Advantage ion trap mass spectrometer (CA, USA).
Quantification of index compounds (1 and 2) in the chromatogram of known
concentrations of the three tissue extracts was calculated on the basis of a standard
calibration curve of the individual index compounds. The metabolite profiles and
the relative content of the two index compounds were routinely used for quality
control of the specific test tissue extracts [29]. The total content of alkylamides in
the [F], [R], and [S+L] extracts of E. purpureawas also quantitatively determined.
We observed that nine major alkylamide compounds could be readily detected in
our RP-HPLC analyses. The nine alkylamides in E. purpurea extracts were then
characterized and quantified. The total amount of alkylamides present in the
specific tissue extracts was calculated by the summation of the contents of the nine
alkylamides detected in the chromatogram of a known concentration of a specific
tissue extract, using a standard calibration curve of the alkylamides. The
alkylamide concentrations in the [F], [S+L], and [R] extracts of E. purpurea
were determined to be approximately 0.39, 0.10, and 3.01% (in dry weight of test
plant extracts), respectively.Acknowledgments
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